Dermata Therapeutics, Inc. (NASDAQ: DRMA) reported Q1 EPS of ($2.27), $2.07 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Dermata Therapeutics, Inc. (DRMA) click here.